Comparing an experimental drug to standard chemo for ovarian cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests a new drug called BL-B01D1 against standard chemotherapy for people with ovarian cancer that no longer responds to platinum-based treatments. The goal is to see which option works better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with ovarian, fallopian tube, or primary peritoneal cancer that has come back after platinum chemotherapy.
- You have had 1 to 3 previous treatments for your cancer, and the last one stopped working or caused side effects that were too severe to continue.
- Your doctor has confirmed that your cancer has a measurable tumor on a scan.
- You are well enough to be up and about (ECOG score 0 or 1) and have a life expectancy of at least 3 months.
- If you have a specific receptor called FR alpha on your cancer cells, you must have already tried a drug called mirvetuximab soravtansine.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares an investigational drug called BL-M07D1 with standard chemotherapy for women whose ovarian, fallopian tube, or primary peritoneal cancer has come back despite previous platinum-based treatment. The goal is to see if BL-M07D1 is more effective than the doctor's choice of chemotherapy.
This trial tests a new drug, AZD5335, against standard treatments (mirvetuximab soravtansine or chemotherapy) for women with platinum-resistant ovarian cancer. It aims to see if AZD5335 works better based on the level of a protein called FRα on your tumor cells.
This trial tests an investigational drug called TORL-1-23 for people with ovarian cancer that has stopped responding to platinum chemotherapy. It aims to see if the drug can help shrink or control the cancer.
This trial tests a new drug called BL-B01D1 against standard chemotherapy for people with advanced bladder cancer that has stopped responding to platinum chemo and immunotherapy. The goal is to see if the new drug works better.
This Phase 1/2 study tests BL-B01D1 in people with recurrent or metastatic gynecologic cancers (such as ovarian, uterine, or cervical cancer) when standard treatments have failed or aren’t options. It focuses on how well the drug works and whether it can be given safely.
This study tests a new drug called SHR-A1921 for people with ovarian cancer that no longer responds to platinum chemotherapy. The goal is to see if it can shrink tumors or slow the cancer's growth.
Hear when a new Epithelial Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.